Skip to main content
TipRanks
Go Ultimate75% OFF

Austar Lifesciences Ltd. (6118) AI Stock Analysis

1 Followers
HK:6118

Austar Lifesciences Ltd.

(HKEX:6118)

Select Model
Rating:54Neutral
Price Target:HKD 0.52â–¼(-1.90% Downside)
Action:reiterated
Date:11/18/26

The overall score is constrained primarily by declining revenue, low profitability, weak technical momentum, and inconsistent cash conversion. Reduced leverage, improving profitability, positive 2025 cash flow, and a moderate P/E provide partial support.

Positive Factors
Profitability recoveryThe return to positive net income, EBIT, and EBITDA shows meaningful recovery from the 2023 loss and improves the company’s ability to fund operations internally. If maintained, this rebound can support reinvestment and strengthen financial resilience over the next several quarters.
Negative Factors
Thin profitability and returnsThe earnings recovery remains economically thin because margins are well below earlier levels and returns on equity are modest. Limited profitability leaves less protection against execution pressure and reduces the amount of capital that can be reinvested for durable growth.

Austar Lifesciences Ltd. (6118) vs. iShares MSCI Hong Kong ETF (EWH)

-50%-40%-30%-20%-10%0%10%20%HK:6118-45.88%EWH+4.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 253.73M
Dividend Yield
―
Average Volume (3M)
76.59K
Price to Earnings (P/E)
13.3
Beta (1Y)
0.86
Revenue Growth
14.04%
EPS Growth
-49.19%
Country
Hong Kong
Employees
1,468
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Austar Lifesciences Ltd. Business Overview & Revenue Model

Company Description

Austar Lifesciences Limited functions as an investment holding company, delivering integrated engineering and technology solutions to pharmaceutical production facilities and research institutions globally, with a significant presence in Mainland Chi...

How the Company Makes Money

Austar Lifesciences Ltd. generates revenue primarily by selling products and delivering services to customers in the life sciences and biopharmaceutical ecosystem. Key revenue streams typically include (1) distribution and sales of laboratory and bio...

Austar Lifesciences Ltd. Financial Statement Overview

Summary

Financial performance is mixed: lower debt, positive 2025 profit, and positive operating cash flow support the score, but sharp revenue declines, thin margins, and inconsistent cash conversion remain significant risks.

Income Statement

45Neutral

Balance Sheet

75Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.60B1.53B1.50B1.76B2.16B2.02B
Gross Profit290.37M293.27M301.22M336.05M488.80M479.01M
EBITDA77.75M92.28M87.88M25.15M159.79M148.54M
Net Income17.15M33.80M16.08M-113.47M87.46M277.30M
Balance Sheet
Total Assets2.14B2.13B2.08B2.16B2.39B2.04B
Cash, Cash Equivalents and Short-Term Investments255.32M276.59M167.81M173.76M148.13M219.74M
Total Debt268.24M343.82M401.95M496.20M336.55M155.22M
Total Liabilities1.31B1.30B1.29B1.38B1.51B1.26B
Stockholders Equity831.23M822.90M791.41M773.01M896.94M786.58M
Cash Flow
Free Cash Flow152.42M99.74M78.31M-133.59M-155.25M-204.02M
Operating Cash Flow186.17M128.24M98.81M-62.65M-37.93M-103.45M
Investing Cash Flow-35.54M-15.58M4.43M-54.47M-153.14M65.02M
Financing Cash Flow-93.12M-42.76M-101.32M147.12M125.30M59.35M

Austar Lifesciences Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price0.53

Price Trends

50DMA0.64Negative
100DMA0.67Negative
200DMA0.73Negative

Market Momentum

MACD-0.03Negative
RSI38.58Neutral
STOCH64.81Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6118, the sentiment is Negative. The current price of 0.53 is below the 20-day moving average (MA) of 0.54, below the 50-day MA of 0.64, and below the 200-day MA of 0.73, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 38.58 is Neutral, neither overbought nor oversold. The STOCH value of 64.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6118.

Austar Lifesciences Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:6118 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:1612HK:161264NeutralHKD 455.47M4.5713.95%6.76%10.95%9.26%
HK:6118HK:611854NeutralHKD 269.11M13.342.07%―14.04%-49.19%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:2170HK:217044NeutralHKD 369.26M-1.71-19.34%―-2.28%24.76%
HK:2297HK:229740UnderperformHKD 207.40M-2.67-19.46%―4.35%43.23%
HK:2500HK:250039UnderperformHKD 405.73M-0.69-28.24%―-38.15%25.70%
HK:2216HK:221628UnderperformHKD 256.44M-1.64-12.45%―――

* Healthcare Sector Average

Performance Comparison

-50%0%50%HK:6118HK:1612HK:2170HK:2216HK:2297HK:2500Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:6118 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:6118Austar Lifesciences Ltd.0.53-0.41-44.15%
HK:1612Vincent Medical Holdings Limited0.68-0.08-10.76%
HK:2170Suzhou Basecare Medical Corp. Ltd. Class H1.28-0.78-37.92%
HK:2216Broncus Holding Corp.0.48-2.01-80.72%
HK:2297Rainmed Medical Limited0.15-0.12-44.44%
HK:2500Venus Medtech (Hangzhou), Inc. Class H0.86-1.45-62.72%

Austar Lifesciences Ltd. Corporate Events

Austar Lifesciences Grows Revenue but Interim Profit Slides on Margin Pressure

Aug 25, 2026

Austar Lifesciences reported unaudited interim results for the six months ended 30 June 2026 showing revenue rising to RMB744.5 million from RMB661.9 million a year earlier, but gross profit slipped slightly to RMB138.1 million as the margin narrowed...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026